Cargando…
A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database
INTRODUCTION: Squamous cell carcinoma (SqCC) is the second most common histology of primary bladder cancer, but still very limited information is known about its treatment outcomes. Most bladder cancer trials have excluded SqCC, and the current treatment paradigm for localized SqCC is extrapolated f...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304339/ https://www.ncbi.nlm.nih.gov/pubmed/30656221 http://dx.doi.org/10.1016/j.ctro.2018.12.001 |
_version_ | 1783382337301512192 |
---|---|
author | Fischer-Valuck, Benjamin W. Michalski, Jeff M. Contreras, Jessika A. Brenneman, Randall Christodouleas, John P. Abraham, Christopher D. Kim, Eric H. Arora, Vivek K. Bullock, Arnold D. Carmona, Ruben Figenshau, Robert S. Grubb, Robert Knoche, Eric M. Pachynski, Russell K. Picus, Joel Roth, Bruce J. Sargos, Paul Andriole, Gerald L. Gay, Hiram A. Baumann, Brian C. |
author_facet | Fischer-Valuck, Benjamin W. Michalski, Jeff M. Contreras, Jessika A. Brenneman, Randall Christodouleas, John P. Abraham, Christopher D. Kim, Eric H. Arora, Vivek K. Bullock, Arnold D. Carmona, Ruben Figenshau, Robert S. Grubb, Robert Knoche, Eric M. Pachynski, Russell K. Picus, Joel Roth, Bruce J. Sargos, Paul Andriole, Gerald L. Gay, Hiram A. Baumann, Brian C. |
author_sort | Fischer-Valuck, Benjamin W. |
collection | PubMed |
description | INTRODUCTION: Squamous cell carcinoma (SqCC) is the second most common histology of primary bladder cancer, but still very limited information is known about its treatment outcomes. Most bladder cancer trials have excluded SqCC, and the current treatment paradigm for localized SqCC is extrapolated from results in urothelial carcinoma (UC). In particular, there is limited data on the efficacy of definitive chemo-radiotherapy (CRT). In this study, we compare overall survival outcomes between SqCC and UC patients treated with definitive CRT. MATERIALS/METHODS: We queried the National Cancer Database (NCDB) for muscle-invasive (cT2-T4 N0 M0) bladder cancer patients diagnosed from 2004 to 2013 who underwent concurrent CRT. Propensity matching was performed to match patients with SqCC to those with UC. OS was analyzed using the Kaplan-Meier survival method, and the log-rank test and Cox regression were used for analyses. RESULTS: 3332 patients met inclusion criteria of which 79 (2.3%) had SqCC. 73.4% of SqCC patients had clinical T2 disease compared to 82.5% of UC patients. Unadjusted median OS for SqCC patients was 15.6 months (95% CI, 11.7–19.6) versus 29.1 months (95% CI, 27.5–30.7) for those with UC (P < 0.0001). On multivariable analysis, factors associated with worse OS included: SqCC histology [HR: 1.53 (95% CI, 1.19–1.97); P = 0.001], increasing age [HR: 1.02 (95% CI, 1.02–1.03); P < 0.0001], increasing clinical T-stage [HR: 1.21 (95% CI, 1.13–1.29); P < 0.0001], and Charlson-Deyo comorbidity index [HR: 1.26 (95% CI, 1.18–1.33); P < 0.0001]. Seventy-seven SqCC patients were included in the propensity-matched analysis (154 total patients) with a median OS for SqCC patients of 15.1 months (95% CI, 11.1–18.9) vs. 30.4 months (95% CI, 19.4–41.4) for patients with UC (P = 0.013). CONCLUSIONS: This is the largest study to-date assessing survival outcomes for SqCC of the bladder treated with CRT. In this study, SqCC had worse overall survival compared to UC patients. Histology had a greater impact on survival than increasing T-stage, suggesting that histology should be an important factor when determining a patient’s treatment strategy and that treatment intensification in this subgroup may be warranted. |
format | Online Article Text |
id | pubmed-6304339 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-63043392019-01-17 A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database Fischer-Valuck, Benjamin W. Michalski, Jeff M. Contreras, Jessika A. Brenneman, Randall Christodouleas, John P. Abraham, Christopher D. Kim, Eric H. Arora, Vivek K. Bullock, Arnold D. Carmona, Ruben Figenshau, Robert S. Grubb, Robert Knoche, Eric M. Pachynski, Russell K. Picus, Joel Roth, Bruce J. Sargos, Paul Andriole, Gerald L. Gay, Hiram A. Baumann, Brian C. Clin Transl Radiat Oncol Article INTRODUCTION: Squamous cell carcinoma (SqCC) is the second most common histology of primary bladder cancer, but still very limited information is known about its treatment outcomes. Most bladder cancer trials have excluded SqCC, and the current treatment paradigm for localized SqCC is extrapolated from results in urothelial carcinoma (UC). In particular, there is limited data on the efficacy of definitive chemo-radiotherapy (CRT). In this study, we compare overall survival outcomes between SqCC and UC patients treated with definitive CRT. MATERIALS/METHODS: We queried the National Cancer Database (NCDB) for muscle-invasive (cT2-T4 N0 M0) bladder cancer patients diagnosed from 2004 to 2013 who underwent concurrent CRT. Propensity matching was performed to match patients with SqCC to those with UC. OS was analyzed using the Kaplan-Meier survival method, and the log-rank test and Cox regression were used for analyses. RESULTS: 3332 patients met inclusion criteria of which 79 (2.3%) had SqCC. 73.4% of SqCC patients had clinical T2 disease compared to 82.5% of UC patients. Unadjusted median OS for SqCC patients was 15.6 months (95% CI, 11.7–19.6) versus 29.1 months (95% CI, 27.5–30.7) for those with UC (P < 0.0001). On multivariable analysis, factors associated with worse OS included: SqCC histology [HR: 1.53 (95% CI, 1.19–1.97); P = 0.001], increasing age [HR: 1.02 (95% CI, 1.02–1.03); P < 0.0001], increasing clinical T-stage [HR: 1.21 (95% CI, 1.13–1.29); P < 0.0001], and Charlson-Deyo comorbidity index [HR: 1.26 (95% CI, 1.18–1.33); P < 0.0001]. Seventy-seven SqCC patients were included in the propensity-matched analysis (154 total patients) with a median OS for SqCC patients of 15.1 months (95% CI, 11.1–18.9) vs. 30.4 months (95% CI, 19.4–41.4) for patients with UC (P = 0.013). CONCLUSIONS: This is the largest study to-date assessing survival outcomes for SqCC of the bladder treated with CRT. In this study, SqCC had worse overall survival compared to UC patients. Histology had a greater impact on survival than increasing T-stage, suggesting that histology should be an important factor when determining a patient’s treatment strategy and that treatment intensification in this subgroup may be warranted. Elsevier 2018-12-12 /pmc/articles/PMC6304339/ /pubmed/30656221 http://dx.doi.org/10.1016/j.ctro.2018.12.001 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Fischer-Valuck, Benjamin W. Michalski, Jeff M. Contreras, Jessika A. Brenneman, Randall Christodouleas, John P. Abraham, Christopher D. Kim, Eric H. Arora, Vivek K. Bullock, Arnold D. Carmona, Ruben Figenshau, Robert S. Grubb, Robert Knoche, Eric M. Pachynski, Russell K. Picus, Joel Roth, Bruce J. Sargos, Paul Andriole, Gerald L. Gay, Hiram A. Baumann, Brian C. A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database |
title | A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database |
title_full | A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database |
title_fullStr | A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database |
title_full_unstemmed | A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database |
title_short | A propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the National Cancer Database |
title_sort | propensity analysis comparing definitive chemo-radiotherapy for muscle-invasive squamous cell carcinoma of the bladder vs. urothelial carcinoma of the bladder using the national cancer database |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304339/ https://www.ncbi.nlm.nih.gov/pubmed/30656221 http://dx.doi.org/10.1016/j.ctro.2018.12.001 |
work_keys_str_mv | AT fischervaluckbenjaminw apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT michalskijeffm apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT contrerasjessikaa apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT brennemanrandall apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT christodouleasjohnp apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT abrahamchristopherd apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT kimerich apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT aroravivekk apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT bullockarnoldd apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT carmonaruben apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT figenshauroberts apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT grubbrobert apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT knocheericm apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT pachynskirussellk apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT picusjoel apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT rothbrucej apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT sargospaul apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT andriolegeraldl apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT gayhirama apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT baumannbrianc apropensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT fischervaluckbenjaminw propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT michalskijeffm propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT contrerasjessikaa propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT brennemanrandall propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT christodouleasjohnp propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT abrahamchristopherd propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT kimerich propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT aroravivekk propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT bullockarnoldd propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT carmonaruben propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT figenshauroberts propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT grubbrobert propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT knocheericm propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT pachynskirussellk propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT picusjoel propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT rothbrucej propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT sargospaul propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT andriolegeraldl propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT gayhirama propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase AT baumannbrianc propensityanalysiscomparingdefinitivechemoradiotherapyformuscleinvasivesquamouscellcarcinomaofthebladdervsurothelialcarcinomaofthebladderusingthenationalcancerdatabase |